Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36
Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ: EWTX ) with a Neutral and raises the price target from $32 to $36.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.